Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma
A child near death with an ALK-fusion–positive high-grade glioma refractory to standard treatment had a dramatic response when treatment with lorlatinib was begun. The drug was stopped once the child had an apparent complete remission, but treatment with lorlatinib resumed when relapse occurred 6 mo...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2021-08, Vol.385 (8), p.761-763 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 763 |
|---|---|
| container_issue | 8 |
| container_start_page | 761 |
| container_title | The New England journal of medicine |
| container_volume | 385 |
| creator | Bagchi, Aditi Orr, Brent A Campagne, Olivia Dhanda, Sandeep Nair, Sreenath Tran, Quynh Christensen, Anthony M Gajjar, Amar Furtado, Larissa V Vasilyeva, Aksana Boop, Frederick Stewart, Clinton Robinson, Giles W |
| description | A child near death with an ALK-fusion–positive high-grade glioma refractory to standard treatment had a dramatic response when treatment with lorlatinib was begun. The drug was stopped once the child had an apparent complete remission, but treatment with lorlatinib resumed when relapse occurred 6 months later. At this time, the child is attending preschool and has normal neurologic function. |
| doi_str_mv | 10.1056/NEJMc2101264 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8672682</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2562537323</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-5c28507bbd75eccc794653339b580cbdb72e870b7e1d85e41f334cdd66d7e2643</originalsourceid><addsrcrecordid>eNptkLtOwzAUhi0EoqWwMaNIMBLw3cmCVCraAuUywGwltktdJXGxUxAb78Ab8iQYFRBIeDmDP33nPz8AuwgeIcj48fXZxZXCCCLM6RroIkZISink66ALIc5SKnLSAVshzGF8iOaboEMiIAjNu-B04nxVtLaxZWKbpEgGM1vp5Nm2s6Q_uUyHy2Bd8_76duuCbe2TScb2YZaOfKFNMqqsq4ttsDEtqmB2vmYP3A_P7gbjdHIzOh_0J6miMGtTpnDGoChLLZhRSomc8piV5CXLoCp1KbDJBCyFQTpjhqIpIVRpzbkWJt5GeuBk5V0sy9poZZrWF5VceFsX_kW6wsq_P42dyQf3JDMuMM9wFOx_Cbx7XJrQyrlb-iZmlphxzIggmETqcEUp70LwZvqzAUH52bj83XjE936n-oG_K47AwQqo6yAbM6__93wAoquGiA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2562537323</pqid></control><display><type>article</type><title>Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma</title><source>MEDLINE</source><source>New England Journal of Medicine Current</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><creator>Bagchi, Aditi ; Orr, Brent A ; Campagne, Olivia ; Dhanda, Sandeep ; Nair, Sreenath ; Tran, Quynh ; Christensen, Anthony M ; Gajjar, Amar ; Furtado, Larissa V ; Vasilyeva, Aksana ; Boop, Frederick ; Stewart, Clinton ; Robinson, Giles W</creator><creatorcontrib>Bagchi, Aditi ; Orr, Brent A ; Campagne, Olivia ; Dhanda, Sandeep ; Nair, Sreenath ; Tran, Quynh ; Christensen, Anthony M ; Gajjar, Amar ; Furtado, Larissa V ; Vasilyeva, Aksana ; Boop, Frederick ; Stewart, Clinton ; Robinson, Giles W</creatorcontrib><description>A child near death with an ALK-fusion–positive high-grade glioma refractory to standard treatment had a dramatic response when treatment with lorlatinib was begun. The drug was stopped once the child had an apparent complete remission, but treatment with lorlatinib resumed when relapse occurred 6 months later. At this time, the child is attending preschool and has normal neurologic function.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc2101264</identifier><identifier>PMID: 34407349</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Aminopyridines ; Anaplastic Lymphoma Kinase - antagonists & inhibitors ; Brain Neoplasms - diagnostic imaging ; Brain Neoplasms - drug therapy ; Brain Neoplasms - pathology ; Brain Neoplasms - surgery ; Brain Tumor ; Cancer therapies ; Chemotherapy ; Child, Preschool ; Childhood Cancer ; Childhood Diseases ; Combined Modality Therapy ; Glioma ; Glioma - diagnostic imaging ; Glioma - drug therapy ; Glioma - pathology ; Glioma - surgery ; Hematology ; Humans ; Lactams ; Lactams, Macrocyclic - therapeutic use ; Magnetic Resonance Imaging ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - pathology ; Nervous system ; Neurology ; Neurosurgery ; Oncology ; Pediatrics ; Pyrazoles ; Radiation ; Remission ; Remission Induction ; Surgery ; Surgical outcomes ; Treatments in Oncology ; Tumors</subject><ispartof>The New England journal of medicine, 2021-08, Vol.385 (8), p.761-763</ispartof><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-5c28507bbd75eccc794653339b580cbdb72e870b7e1d85e41f334cdd66d7e2643</citedby><cites>FETCH-LOGICAL-c408t-5c28507bbd75eccc794653339b580cbdb72e870b7e1d85e41f334cdd66d7e2643</cites><orcidid>0000-0001-7441-9486 ; 0000-0003-1381-7434 ; 0000-0001-5466-7685</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc2101264$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2562537323?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,2759,2760,26103,27924,27925,52382,54064,64385,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34407349$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bagchi, Aditi</creatorcontrib><creatorcontrib>Orr, Brent A</creatorcontrib><creatorcontrib>Campagne, Olivia</creatorcontrib><creatorcontrib>Dhanda, Sandeep</creatorcontrib><creatorcontrib>Nair, Sreenath</creatorcontrib><creatorcontrib>Tran, Quynh</creatorcontrib><creatorcontrib>Christensen, Anthony M</creatorcontrib><creatorcontrib>Gajjar, Amar</creatorcontrib><creatorcontrib>Furtado, Larissa V</creatorcontrib><creatorcontrib>Vasilyeva, Aksana</creatorcontrib><creatorcontrib>Boop, Frederick</creatorcontrib><creatorcontrib>Stewart, Clinton</creatorcontrib><creatorcontrib>Robinson, Giles W</creatorcontrib><title>Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>A child near death with an ALK-fusion–positive high-grade glioma refractory to standard treatment had a dramatic response when treatment with lorlatinib was begun. The drug was stopped once the child had an apparent complete remission, but treatment with lorlatinib resumed when relapse occurred 6 months later. At this time, the child is attending preschool and has normal neurologic function.</description><subject>Aminopyridines</subject><subject>Anaplastic Lymphoma Kinase - antagonists & inhibitors</subject><subject>Brain Neoplasms - diagnostic imaging</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - surgery</subject><subject>Brain Tumor</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Child, Preschool</subject><subject>Childhood Cancer</subject><subject>Childhood Diseases</subject><subject>Combined Modality Therapy</subject><subject>Glioma</subject><subject>Glioma - diagnostic imaging</subject><subject>Glioma - drug therapy</subject><subject>Glioma - pathology</subject><subject>Glioma - surgery</subject><subject>Hematology</subject><subject>Humans</subject><subject>Lactams</subject><subject>Lactams, Macrocyclic - therapeutic use</subject><subject>Magnetic Resonance Imaging</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Nervous system</subject><subject>Neurology</subject><subject>Neurosurgery</subject><subject>Oncology</subject><subject>Pediatrics</subject><subject>Pyrazoles</subject><subject>Radiation</subject><subject>Remission</subject><subject>Remission Induction</subject><subject>Surgery</subject><subject>Surgical outcomes</subject><subject>Treatments in Oncology</subject><subject>Tumors</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkLtOwzAUhi0EoqWwMaNIMBLw3cmCVCraAuUywGwltktdJXGxUxAb78Ab8iQYFRBIeDmDP33nPz8AuwgeIcj48fXZxZXCCCLM6RroIkZISink66ALIc5SKnLSAVshzGF8iOaboEMiIAjNu-B04nxVtLaxZWKbpEgGM1vp5Nm2s6Q_uUyHy2Bd8_76duuCbe2TScb2YZaOfKFNMqqsq4ttsDEtqmB2vmYP3A_P7gbjdHIzOh_0J6miMGtTpnDGoChLLZhRSomc8piV5CXLoCp1KbDJBCyFQTpjhqIpIVRpzbkWJt5GeuBk5V0sy9poZZrWF5VceFsX_kW6wsq_P42dyQf3JDMuMM9wFOx_Cbx7XJrQyrlb-iZmlphxzIggmETqcEUp70LwZvqzAUH52bj83XjE936n-oG_K47AwQqo6yAbM6__93wAoquGiA</recordid><startdate>20210819</startdate><enddate>20210819</enddate><creator>Bagchi, Aditi</creator><creator>Orr, Brent A</creator><creator>Campagne, Olivia</creator><creator>Dhanda, Sandeep</creator><creator>Nair, Sreenath</creator><creator>Tran, Quynh</creator><creator>Christensen, Anthony M</creator><creator>Gajjar, Amar</creator><creator>Furtado, Larissa V</creator><creator>Vasilyeva, Aksana</creator><creator>Boop, Frederick</creator><creator>Stewart, Clinton</creator><creator>Robinson, Giles W</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7441-9486</orcidid><orcidid>https://orcid.org/0000-0003-1381-7434</orcidid><orcidid>https://orcid.org/0000-0001-5466-7685</orcidid></search><sort><creationdate>20210819</creationdate><title>Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma</title><author>Bagchi, Aditi ; Orr, Brent A ; Campagne, Olivia ; Dhanda, Sandeep ; Nair, Sreenath ; Tran, Quynh ; Christensen, Anthony M ; Gajjar, Amar ; Furtado, Larissa V ; Vasilyeva, Aksana ; Boop, Frederick ; Stewart, Clinton ; Robinson, Giles W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-5c28507bbd75eccc794653339b580cbdb72e870b7e1d85e41f334cdd66d7e2643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aminopyridines</topic><topic>Anaplastic Lymphoma Kinase - antagonists & inhibitors</topic><topic>Brain Neoplasms - diagnostic imaging</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - surgery</topic><topic>Brain Tumor</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Child, Preschool</topic><topic>Childhood Cancer</topic><topic>Childhood Diseases</topic><topic>Combined Modality Therapy</topic><topic>Glioma</topic><topic>Glioma - diagnostic imaging</topic><topic>Glioma - drug therapy</topic><topic>Glioma - pathology</topic><topic>Glioma - surgery</topic><topic>Hematology</topic><topic>Humans</topic><topic>Lactams</topic><topic>Lactams, Macrocyclic - therapeutic use</topic><topic>Magnetic Resonance Imaging</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Nervous system</topic><topic>Neurology</topic><topic>Neurosurgery</topic><topic>Oncology</topic><topic>Pediatrics</topic><topic>Pyrazoles</topic><topic>Radiation</topic><topic>Remission</topic><topic>Remission Induction</topic><topic>Surgery</topic><topic>Surgical outcomes</topic><topic>Treatments in Oncology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bagchi, Aditi</creatorcontrib><creatorcontrib>Orr, Brent A</creatorcontrib><creatorcontrib>Campagne, Olivia</creatorcontrib><creatorcontrib>Dhanda, Sandeep</creatorcontrib><creatorcontrib>Nair, Sreenath</creatorcontrib><creatorcontrib>Tran, Quynh</creatorcontrib><creatorcontrib>Christensen, Anthony M</creatorcontrib><creatorcontrib>Gajjar, Amar</creatorcontrib><creatorcontrib>Furtado, Larissa V</creatorcontrib><creatorcontrib>Vasilyeva, Aksana</creatorcontrib><creatorcontrib>Boop, Frederick</creatorcontrib><creatorcontrib>Stewart, Clinton</creatorcontrib><creatorcontrib>Robinson, Giles W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bagchi, Aditi</au><au>Orr, Brent A</au><au>Campagne, Olivia</au><au>Dhanda, Sandeep</au><au>Nair, Sreenath</au><au>Tran, Quynh</au><au>Christensen, Anthony M</au><au>Gajjar, Amar</au><au>Furtado, Larissa V</au><au>Vasilyeva, Aksana</au><au>Boop, Frederick</au><au>Stewart, Clinton</au><au>Robinson, Giles W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2021-08-19</date><risdate>2021</risdate><volume>385</volume><issue>8</issue><spage>761</spage><epage>763</epage><pages>761-763</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>A child near death with an ALK-fusion–positive high-grade glioma refractory to standard treatment had a dramatic response when treatment with lorlatinib was begun. The drug was stopped once the child had an apparent complete remission, but treatment with lorlatinib resumed when relapse occurred 6 months later. At this time, the child is attending preschool and has normal neurologic function.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>34407349</pmid><doi>10.1056/NEJMc2101264</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-7441-9486</orcidid><orcidid>https://orcid.org/0000-0003-1381-7434</orcidid><orcidid>https://orcid.org/0000-0001-5466-7685</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2021-08, Vol.385 (8), p.761-763 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8672682 |
| source | MEDLINE; New England Journal of Medicine Current; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland |
| subjects | Aminopyridines Anaplastic Lymphoma Kinase - antagonists & inhibitors Brain Neoplasms - diagnostic imaging Brain Neoplasms - drug therapy Brain Neoplasms - pathology Brain Neoplasms - surgery Brain Tumor Cancer therapies Chemotherapy Child, Preschool Childhood Cancer Childhood Diseases Combined Modality Therapy Glioma Glioma - diagnostic imaging Glioma - drug therapy Glioma - pathology Glioma - surgery Hematology Humans Lactams Lactams, Macrocyclic - therapeutic use Magnetic Resonance Imaging Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Nervous system Neurology Neurosurgery Oncology Pediatrics Pyrazoles Radiation Remission Remission Induction Surgery Surgical outcomes Treatments in Oncology Tumors |
| title | Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T07%3A19%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lorlatinib%20in%20a%20Child%20with%20ALK-Fusion%E2%80%93Positive%20High-Grade%20Glioma&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Bagchi,%20Aditi&rft.date=2021-08-19&rft.volume=385&rft.issue=8&rft.spage=761&rft.epage=763&rft.pages=761-763&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc2101264&rft_dat=%3Cproquest_pubme%3E2562537323%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2562537323&rft_id=info:pmid/34407349&rfr_iscdi=true |